(Q37712223)

22 August 2017

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial (English)

1 reference

22 August 2017

0 references

1 reference

Susan L Greenspan

1

1 reference

22 August 2017

Adam Brufsky

2

1 reference

22 August 2017

Barry C Lembersky

3

1 reference

22 August 2017

Rajib Bhattacharya

4

1 reference

22 August 2017

Karen T Vujevich

5

1 reference

22 August 2017

Subashan Perera

6

1 reference

22 August 2017

Susan M Sereika

7

1 reference

22 August 2017

Victor G Vogel

8

1 reference

22 August 2017

language of work or name

English

0 references

publication date

21 April 2008

1 reference

Journal of Clinical Oncology

22 August 2017

1 reference

22 August 2017

26

1 reference

22 August 2017

16

1 reference

22 August 2017

2644-2652

1 reference

Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Aromatase inhibitors and bone health in women with breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Aromatase inhibitors and bone loss

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Skeletal integrity in patients with nail patella syndrome

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Osteoporosis due to cancer treatment: pathogenesis and management

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Global trends in breast cancer incidence and mortality 1973-1997.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Gonadal dysfunction in patients receiving chemotherapy for cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3992822

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 September 2018

1 reference

12 December 2020

Dietary calcium intake and bone loss from the spine in healthy postmenopausal women

1 reference

12 December 2020

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates

1 reference

12 December 2020

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

12 December 2020

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

12 December 2020

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

12 December 2020

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

Bone density in breast cancer: when to intervene?

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2007.15.2967

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

18427147

1 reference